CYCN
NASDAQCyclerion Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.37+2.17 (+10.14%)
2026-06-042026-09-08
News · 26 weeks40+89%
2026-03-222026-09-13
Mix3290d
- Insider15(47%)
- SEC Filings14(44%)
- Other3(9%)
Latest news
25 items- SECSEC Form SCHEDULE 13D filed by Cyclerion Therapeutics Inc.SCHEDULE 13D - Korsana Biosciences, Inc. (0001755237) (Subject)
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - Korsana Biosciences, Inc. (0001755237) (Filer)
- INSIDERSEC Form 4 filed by Director Pernice Michelle Patricia4 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 4 filed by Director Shah Nimish P4 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 4 filed by Director Gottesdiener Andrew4 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERNew insider Violin Jonathan claimed ownership of 207,400 shares (SEC Form 3)3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 3 filed by new insider Leoni Matthew James3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pernice Michelle Patricia3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 3 filed by new insider Henson Heidi3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gottesdiener Andrew3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERNew insider Fairmount Funds Management Llc claimed ownership of 9,103,729 shares (SEC Form 3)3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERNew insider Shah Nimish P claimed ownership of 4,549,585 shares (SEC Form 3)3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vignola Mark J.3 - Korsana Biosciences, Inc. (0001755237) (Issuer)
- SECSEC Form 8-K filed by Cyclerion Therapeutics Inc.8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 8-K filed by Cyclerion Therapeutics Inc.8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- INSIDERChief Financial Officer Chicko Rhonda M. exercised 25,000 shares at a strike of $2.35, increasing direct ownership by 138,889% to 25,018 units (SEC Form 4)4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- INSIDEROfficer Graul Regina Margaret exercised 55,849 shares at a strike of $3.30 and covered exercise/tax liability with 48,629 shares, increasing direct ownership by 7% to 107,523 units (SEC Form 4)4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.SCHEDULE 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
CYCN FAQ
6 questionsWhat does Cyclerion Therapeutics Inc. do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for...Where does CYCN stock trade?
Cyclerion Therapeutics Inc. (CYCN) is listed on NASDAQ.What sector and industry is CYCN in?
Cyclerion Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYCN?
Cyclerion Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Truist Securities: Buy with a $1400.00 price target on 2021-10-20. Recent price targets range from $700.00 to $1400.00.What companies are similar to CYCN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CYCN side-by-side with any of them on Quantisnow.How can I track CYCN on Quantisnow?
Quantisnow aggregates Cyclerion Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYCN to receive live email and push alerts on every new disclosure.